Previous studies have identified JAK1/2i as antiviral agents against HIV infection, blocking both latent and productive infection, in line with our findings for the pan-JAK inhibitor ruxolitinib and JAK2i pacritinib (17, 33). Here, JAK1 is linked to infection.